Indeed, several Smo inhibitors have been approved for treating basal cell carcinomas (BCCs) and neuroblastomas but these inhibitors have little success in cancers that lack the PTCH or SMO gene mutation6. Here, PTCH1 is linked to basal cell carcinoma.